KabirModyMD
Oncology • Jacksonville, FLGastrointestinal Cancer, Complementary and Integrative
Assistant Professor of Medicine and Consultant Vice Chair, Division of Hematology and Oncology
Dr. Mody is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Mayo Clinic
4500 San Pablo Road S
Jacksonville, FL 32224Phone+1 904-953-2795- Is this information wrong?
Summary
- Dr Mody is a GI Oncologist specializing in the care of patients with liver cancers. His research is focused upon immunotherapy and novel drug development for these malignancies. Additionally, his research investigates the use of circulating tumor DNA in the diagnosis and management of hepatobiliary cancers.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2004 - 2007
St. George's University School of MedicineClass of 2004
Columbia University College of Physicians & SurgeonsMS, Human Nutrition, 1999 - 2000
Certifications & Licensure
FL State Medical License 2014 - 2024
CT State Medical License 2008 - 2016
MA State Medical License 2007 - 2010
Clinical Trials
- Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Start of enrollment: 2014 Jun 01
- A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2014 Jul 31
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Start of enrollment: 2017 Sep 27
Publications & Presentations
PubMed
- (HER2) amplifications and co-occurringalterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.Weipert, C., Espenschied, C., Raymond, V., Gordon, E., Barzi, A., Wang-Gillam, A., Nezami, M., Mahadevan, D., Mody, K.> ;Frontiers in Oncology. 2024 Jan 1
- 1 citationsPlain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, Stephen L Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon Koo Kang, Tu Van Dao, Enrico N De To...> ;Future Oncology. 2023 Dec 1
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain, Kristen Spencer, Tri Minh Le, Osama E Rahma, Jordan Maurer, Jen Stanton, Karen Zhang, ...> ;JCO Precision Oncology. 2023 Aug 1
- Join now to see all
Journal Articles
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular CarcinomaMohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
Press Mentions
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to Its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific AdvisorMay 13th, 2022
Can HCC Be Caught Early Using ctDNA?August 22nd, 2019
Alex Trebek's Fight: Why Is Pancreas Cancer Such a Beast?May 2nd, 2019- Join now to see all
Committees
- Co-Chair, Mayo Clinic Cancer Center Hepatobiliary Malignancies Disease Group 2017 - Present
Professional Memberships
- Member
- Member
External Links
- Mayo Websitehttp://www.mayoclinic.org/biographies/mody-kabir-m-d/bio-20097397
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
